DDInter1635 DDInter1055
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Salmeterol {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Levofloxacin
Salmeterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Salmeterol {u} (Compound) causes {v} (Side Effect) Cramp muscle
Cramp muscle {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Salmeterol {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Salmeterol (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Levofloxacin (Compound)
Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levofloxacin (Compound)
Salmeterol (Compound) causes Cramp muscle (Side Effect) and Cramp muscle (Side Effect) is caused by Levofloxacin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Salmeterol (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)